The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension
Open accessAbstract
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension Amber Lundy, Nahla Lutfi, Cherylyn BeckeyVeterans Affairs Medical Center, Pharmacy Service, West Palm Beach, FL, USAAbstract: Nifedipine is a dihydropyridine calcium-channel blocker (CCB) introduced approximately 30 years ago for the prophylaxis of angina symptoms, and then later utilized as an anti-hypertensive agent. In the 1990s, several meta-analyses and a case-control study were published which raised concern regarding increased mortality and increased risk for myocardial infarction with short-acting nifedipine. Further evaluation of these meta-analyses and case control study underscores some important limitations and the need to further elucidate the role of this class of medications in high-risk patients. Until 2000, there was a paucity of data on the long-term effects as well as the long-term outcomes of CCBs in the treatment of stable coronary disease or in patients with manifestations of the disease such as hypertension or angina. While it has been well established that nifedipine and other dihydropyridines lower blood pressure and improve symptoms of angina, several studies were designed to evaluate the effect of dihydropyridines on “hard” outcomes, specifically cardiovascular and cerebrovascular events. In this review, we describe the clinical studies evaluating the use of nifedipine when compared to placebo as well as other anti-hypertensive therapies in an attempt to identify the most appropriate place in therapy for this class of medications and to further clarify its utilization in high-risk patients. Keywords: nifedipine, dihydropyridine, ACTION, calcium-channel blocker, coronary heart disease, hypertension
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
beta Blockade after myocardial infarction: systematic review and meta regression analysis
Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J. (1999) · BMJ · doi:10.1136/bmj.318.7200.1730 · Cited by 1,509
Poole-Wilson, P. A., Lubsen, J., Kirwan, B.-A., van Dalen, F. J., Wagener, G., Danchin, N., Just, H., Fox, K. A., Pocock, S. J., Clayton, T. C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16980-8 · Cited by 511
Metadata
- Authors
- Lundy, A.-L.
- Affiliations
- Veterans Health Administration (US)
- Corresponding author
- Lundy, Amber-Lea
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2009-05
- Volume
- 5
- Issue
- 1
- Pages
- 429
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- PMC
- PMC2686260
- OpenAlex
- W2025382797
- Cited by
- 19
- References
- 3
- Citations by year
- 2022: 1 · 2020: 2 · 2019: 2 · 2014: 5 · 2013: 3 · 2012: 2
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vascular Health and Risk Management (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, other-oa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- nifedipine, dihydropyridine calcium channel blockers, coronary artery disease, hypertension, high-risk patients, cardiovascular outcomes, myocardial infarction risk, ACTION trial, antihypertensive therapy
- MeSH terms
- Antihypertensive Agents, Blood Pressure, Calcium Channel Blockers, Cardiovascular Diseases, Coronary Artery Disease, Humans, Hypertension, Nifedipine, Treatment Outcome, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
